{"doi":"10.1007/s40262-025-01474-8","title":"Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity","abstract":null,"journal":"Clinical Pharmacokinetics","year":2025,"id":636709,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1652772,"name":"Arianna Pannunzio","orcid":null,"position":1,"is_corresponding":false},{"id":1652773,"name":"Erminia Baldacci","orcid":null,"position":2,"is_corresponding":false},{"id":1652774,"name":"Vittoria Cammisotto","orcid":null,"position":3,"is_corresponding":false},{"id":149652,"name":"Valentina Castellani","orcid":null,"position":4,"is_corresponding":false},{"id":1652775,"name":"Rosaria Mormile","orcid":null,"position":5,"is_corresponding":false},{"id":1652777,"name":"Ilaria Maria Palumbo","orcid":null,"position":6,"is_corresponding":false},{"id":1652781,"name":"Antonio Chistolini","orcid":null,"position":7,"is_corresponding":false},{"id":155440,"name":"Francesco Violi","orcid":null,"position":8,"is_corresponding":false},{"id":1652786,"name":"Job Harenberg","orcid":null,"position":9,"is_corresponding":false},{"id":1652787,"name":"Daniele Pastori","orcid":"0000-0001-6357-5213","position":10,"is_corresponding":false},{"id":1652790,"name":"Pasquale Pignatelli","orcid":null,"position":11,"is_corresponding":false},{"id":1652771,"name":"Danilo Menichelli","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Plasma Concentrations of Direct Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Different Degrees of Obesity","abstract":"BACKGROUND: Atrial fibrillation (AF) has multiple cardio-metabolic comorbidities, including obesity. The use of direct oral anticoagulants (DOACs) in patients with AF and obesity is still uncertain owing to the concern of possible ineffective DOAC plasma concentration. We evaluated the peak and trough plasma concentrations of DOACs in AF patients with different degrees of obesity. METHODS: . The 2-hour peak and trough DOAC plasma concentrations were assessed. Intake of DOAC was verified on site. Multivariable logistic regression analysis was used to assess the odds ratio (OR) and 95% confidence interval (95% CI) of factors associated with below-range trough concentration (BRTC) and below-range peak concentration (BRPC). RESULTS: . DOACs prescribed were apixaban (46.8%), rivaroxaban (21.8%), dabigatran (16.4%), and edoxaban (15.0%); 18.1% and 14.4% had BRTC and BRPC concentrations, respectively. Patients with BRTC were more frequently treated with edoxaban and dabigatran and had a higher BMI. On multivariable logistic regression analysis, dabigatran [hazard ratio (HR) 3.039, 95% CI 1.155-7.999, p = 0.024) and BMI ≥ II class (OR 2.625, 95% CI 1.087-6.335, p = 0.032] were associated with BRTC. Dabigatran (OR 4.296, 95% CI 1.523-12.120, p = 0.006) and apixaban (OR 0.277, 95% CI 0.096-0.802, p = 0.018) were directly and inversely associated with BRPC, respectively. CONCLUSIONS: A nonnegligible proportion of patients with obesity and AF have below-range plasma concentrations of DOACs. Assessment of DOAC plasma concentration in obesity class ≥ II may be useful in these patients.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39937335","pmcid":"PMC11954712","openalex_id":"https://openalex.org/W4407391691","authors":[],"funders":[{"funder_name":"Università degli Studi di Roma La Sapienza","grant_id":"","title":null}],"total_grants":1,"fwci":2.255,"citation_percentile":0.87206665,"influential_citations":0,"citation_trend":[{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s40262-025-01474-8.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007/s40262-025-01474-8.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s40262-025-01474-8","host_type":"publisher"},{"url":"https://doi.org/10.1007/s40262-025-01474-8","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39937335","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11954712","host_type":"repository"},{"url":"https://hdl.handle.net/11573/1733750","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11954712/pdf/40262_2025_Article_1474.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11954712","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11954712?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Atrial Fibrillation Management and Outcomes","Cardiovascular Disease and Adiposity","Venous Thromboembolism Diagnosis and Management","Humans","Atrial Fibrillation","Female","Male","Aged","Obesity","Administration, Oral","Aged, 80 and over","Middle Aged","Factor Xa Inhibitors","Body Mass Index","Dabigatran","Pyrazoles","Pyridones","Anticoagulants","Rivaroxaban","Pyridines","Thiazoles"],"mesh_terms":["Rivaroxaban","Dabigatran","Administration, Oral","Aged","Aged, 80 and over","Anticoagulants","Atrial Fibrillation","Female","Humans","Male","Middle Aged","Obesity","Pyrazoles","Pyridines","Pyridones","Thiazoles","Body Mass Index","Factor Xa Inhibitors"],"keywords":["Atrial fibrillation","Obesity","Internal medicine","Cardiology","Medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T17:35:44.332422Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}